US Pharmaceutical Company Novavax Vaccine Also Shows Immune Response to Omicron... Initial Clinical Results Released

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Kwon Jae-hee] The COVID-19 vaccine developed by the U.S. pharmaceutical company Novavax has been shown to elicit an immune response against the Omicron variant.

On the 22nd (local time), major foreign media reported that Novavax announced initial clinical trial data results confirming this.

Novavax stated, "Two doses of the vaccine generated an immune response against the Omicron variant, and the immune response was further enhanced with a booster shot," adding, "Research is also underway to develop a vaccine specifically targeting Omicron."

Previously, other pharmaceutical companies such as Pfizer and Moderna also announced that their COVID vaccines elicited immune responses against Omicron, and that booster shots further increased immunity.

The World Health Organization (WHO) authorized the emergency use of the Novavax vaccine on the 21st, and Novavax plans to soon apply for approval from U.S. health authorities as well.

The Novavax vaccine is administered in two doses at three-week intervals and can be stored refrigerated, making it easier to transport compared to messenger RNA (mRNA) vaccines like Pfizer’s.

This content was produced with the assistance of AI translation services.